Eli Lilly presents positive data from tirzepatide sub-studies

Substudies connected to Eli Lilly's Supass 3 phase III trial have generated favorable results for the candidate when compared to Novo Nordisk's long-acting insulin Tresiba

Photo: Mike Blake/Reuters/Ritzau Scanpix

US-based pharmaceutical company Eli Lilly has presented several positive results for the drug candidate tirzepatide, which is a combination of the two hormones known respectively as GLIP-1 and GIP, at the annual meeting of the European Association for the Study of Diabetes (EASD). The company reports this in two seperate press releases on Thursday.

Eli Lilly's sub-studies, which stem from the company's phase III trial, Surpass-3, show that tirzepatide can lead to less variability in blood sugar levels – including leading to shorter intervals of low blood sugar levels – for adults with type 2 diabetes, compared with Novo Nordisk's long-acting insulin Tresiba.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs